Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Test Detects Early Mouth Cancer

By LabMedica International staff writers
Posted on 24 Oct 2012
A gene test that can detect precancerous cells in patients with benign-looking mouth lesions could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival. More...


The test is less invasive than the standard histopathology methods as it requires only a 1-2 mm piece of tissue and it takes less than three hours to get the results, compared to up to a week for standard histopathology where biopsy tissue taken during an operation is examined under a microscope by a pathologist.

Scientists at Queen Mary, University of London (UK) showed that the quantitative Malignancy Index Diagnostic System (qMIDS) test had a cancer detection rate of 91% to 94% when used on more than 350 head and neck tissue specimens from 299 patients in the UK and Norway. The qMIDS test measures the levels of 16 genes, which are converted, via a diagnostic algorithm, into a "malignancy index" which quantifies the risk of the lesion becoming cancerous.

The test is based on a cancer gene encoding the Forkhead box protein (FOXM1) - (isoform B). The FOXM1 gene is highly expressed in many cancer types. The 14 associated genes are implicated in the regulation of the cell cycle, differentiation, aging, genomic stability, epigenetic and stem cell renewal. Two reference genes are included in the test.

Diagnostic test performance was assessed using detection rate (DR) and false-positive rate (FPR).The median qMIDS scores were 1.3, in healthy tissue, 2.9 in dysplasia, and 6.7 in head and neck squamous cell carcinomas (HNSCC).. At a qMIDS cut-off of 4.0, DR was 94% and FPR was 3.2% for a Norwegian dataset; and DR was 91% and FPR was 1.3% for the UK dataset. In this study, the investigators further demonstrated the transferability of qMIDS for diagnosing 58 premalignant human vulva and 21 skin squamous cell carcinomas, illustrating its potential clinical use for other cancer types.

Mouth cancer affects more than 6,200 people in the UK each year and more than half a million people worldwide, with global figures estimated to rise above one million a year by 2030. Muy-Teck Teh, PhD, the lead investigator and inventor of the test, said, “A sensitive test capable of quantifying a patient's cancer risk is needed to avoid the adoption of a 'wait-and-see' intervention. Detecting cancer early, coupled with appropriate treatment can significantly improve patient outcomes, reduce mortality and alleviate long-term public healthcare costs.” The study was published on October 4, 2012, in the journal International Journal of Cancer.

Related Links:

Queen Mary, University of London



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gastrointestinal Panel
Xpert® GI Panel
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.